[Form 4] NeuroOne Medical Technologies Corporation Insider Trading Activity

Rhea-AI Filing Summary

Form 4 filing overview: On 06/23/2025, NeuroOne Medical Technologies Corp. (NMTC) director Jeffrey S. Mathiesen received an option to purchase 50,000 shares of common stock at an exercise price of $0.662 per share. The option vests in twelve equal monthly installments over one year and carries an expiration date of 06/23/2035. Following the grant, Mathiesen now beneficially owns 50,000 derivative securities directly.

No open-market purchases or sales of common shares were reported, and no changes to previously held positions were disclosed. The transaction appears to be standard board compensation designed to align the director’s interests with shareholders while creating only modest potential dilution.

Insights

Corporate Governance Expert

TL;DR Routine director option grant; governance-neutral, low dilution.

The 50,000-share option award is a typical equity retainer for small-cap boards and follows standard vesting (12 monthly tranches). The $0.662 strike matches recent trading ranges, suggesting no preferential pricing. Because the option represents a small percentage of NMTC’s outstanding shares, shareholder dilution risk is minimal. The filing does not signal insider sentiment through buying or selling of existing shares; therefore, governance impact is neutral.

Securities Analyst

TL;DR Minimal market impact; purely compensatory option grant.

From a market perspective, the grant neither indicates bullish insider conviction nor bearish pressure. It adds a modest 50,000 potential shares versus NMTC’s float, an immaterial figure for valuation models. Investors should view this as routine compensation with no immediate earnings or cash-flow effect. The monthly vesting schedule smooths any future share issuance, mitigating supply shocks. Overall trading sentiment for NMTC remains unchanged.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MATHIESEN JEFFREY S

(Last) (First) (Middle)

7599 ANAGRAM DR.

(Street)

EDEN PRAIRIE MN 55344

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NEUROONE MEDICAL TECHNOLOGIES Corp [ NMTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	$0.662	06/23/2025		A		50,000		(1)	06/23/2035	Common Stock	50,000	$0	50,000	D

Explanation of Responses:

1. The option vests in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month.

	/s/ Emily Johns, by Power of Attorney	06/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many stock options did NMTC director Jeffrey S. Mathiesen receive?

He was granted 50,000 options to purchase NMTC common stock.

What is the exercise price of the newly granted NMTC options?

The exercise (conversion) price is $0.662 per share.

When do the 50,000 NMTC options vest?

They vest in 12 equal monthly installments over one year, with vesting at the end of each month.

What is the expiration date of the options granted to Jeffrey S. Mathiesen?

The options expire on 06/23/2035.

Did the Form 4 report any sale of NMTC shares?

No. The filing only reported the acquisition of derivative options; no share sales were disclosed.

How many derivative securities does Mathiesen own after this transaction?

He beneficially owns 50,000 derivative securities following the grant.